Cancer Drug Blockbusters

Date: November 22, 2010
Pages: 170
Price:
US$ 2,265.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C7B9A8CFF7BEN
Leaflet:

Download PDF Leaflet

Cancer Drug Blockbusters
The pursuit of safe and effective cancer medicines dominates research funding and the sector has more blockbuster products than any other therapy area.

There exists a huge variety of cancer treatments, from the widely-used chemotherapeutic agents to the recently-launched, first-in-class cancer vaccine, with many of these treatments achieving blockbuster sales in excess of US$1 billion. However, many existing brands face declining sales due to generic erosion as patents expire, and the rate at which new drugs reach the market is slowing, impacting company revenues.

This report identifies the current oncology blockbuster products and assesses their future market potential, looking at both winners and losers in the competitive landscape to 2016. In addition, it highlights the promising products that, in Espicom’s analysis, will successfully carve out a market share to become the oncology blockbusters of the future. Both current and future marketplaces are analysed from the companies’ perspective, identifying the products on which their relative success or failure rests.

All 21 products featured in this report are also detailed and analysed individually in terms of their current status, mode of action, clinical data, risks associated with their development, expertise of developing/marketing company and the competitive pressures they may face. This analysis is summarised in the form of a unique score that acts as a useful comparative tool and 7-year individual product forecasts are provided to 2016.

Whether you are involved with competitive monitoring, product planning or business development, this new report will provide the facts and insight to fully understand the trends, companies and products which are shaping this critical area of the pharmaceutical industry.

About the Author

This report has been researched by the Espicom product team led by senior Espicom pharmaceutical analyst Sue Viney. For over 10 years Sue has played a pivotal role in tracking trends in drug development and corporate performance. In addition to this report she has produced detailed product analysis in the Breast/Lung/Colorectal/Prostate Cancer, CNS, and Rheumatoid Arthritis sectors.

More Information...

Comprehensive analysis of trends and impacts on companies: assess the winners and losers!

An assessment of key therapeutic approaches – the rise of biologicals

Detailed analysis of 21 products that will dominate the cancer market in the near term

Detailed 7-year sales forecasts to 2016, with sales by indication where appropriate

Answering key questions...
  • Which companies will have increased their market share by 2016?
  • Who will be the new members of the cancer blockbuster club in the future?
  • What are the prospects for hormonal therapies?
  • To what degree will Sprycel, Tasigna and generic competition affect Novartis’ Gleevec?
  • What product extensions did Roche get for Herceptin in 2010?
  • Where to next for Pfizer after it suspended development of Sutent in a range of cancers in September 2009?
  • How might cheaper generic doxetaxel affect sales of Dendreon’s novel vaccine for CRPC patients?
EXECUTIVE SUMMARY

ESPICOM MARKET ANALYSIS

Blockbuster Products
The Winners
The Losers
Patent Expiration
Sales Forecasts to 2016
Competitor Ratio Analysis
Current Blockbuster Market
Blockbuster Market in 2016

BLOCKBUSTER PRODUCTS

Alimta
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Data Exclusivity
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Arimidex
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition Within the Market-place
  Data Exclusivity
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Avastin
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Eloxatin
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Erbitux
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Femara
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Gemzar
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Glivec / Gleevec
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Data Exclusivity
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Herceptin
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast
MabThera / Rituxan
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Nexavar
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Data Exclusivity
  Patent Expiry
  Competitor Ratio Analysis
  Forecast
Provenge
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition Within the Market-place
  Competitor Ratio Analysis
  Forecast
Sutent
  Mode of Action
  Current Status
  Approvals/Filings
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Data Exclusivity
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Tarceva
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Data Exclusivity
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Tasigna
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Data Exclusivity
  Patent Expiry
  Competitor Ratio Analysis
  Forecast
Taxotere
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Data Exclusivity
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Tykerb
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Data Exclusivity
  Patent Expiry
  Competitor Ratio Analysis
  Forecast
Velcade
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Data Exclusivity
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Xeloda
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Patent Expiry
  Competitor Ratio Analysis
  Forecast
Zoladex
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition Within the Market-place
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast
Zometa
  Mode of Action
  Current Status
  Proof of Concept/Clinical Data
  Development Risks
  Company Expertise
  Competition within the Market-place
  Data Exclusivity
  Patent Expiry
  Generic Competition
  Competitor Ratio Analysis
  Forecast

LIST OF TABLES

Major Patent Expiries
Sales Forecasts (US$ millions)
Competitor Ratio Analysis Scores
Oncology Blockbusters by Sales Value, 2009
Oncology Blockbusters by Sales Value, 2016
Alimta Sales by Indication (2008-2016)
FDA ANDA Approvals for Anastrozole
Arimidex Total Sales (2008-2016)
Avastin Sales by Company (2008-2016)
Avastin Sales by Indication (2008-2016)
Eloxatin Sales (2008-2016)
Erbitux Sales by Company (2008-2016)
Femara Sales by Company (2008-2016)
FDA ANDA Approvals for Gemcitabine
Tentative ANDA Approvals for Gemcitabine
Gemzar Sales By Indication (2008-2016)
Glivec/Gleevec Total Sales (2008-2016)
Herceptin Sales by Company (2008-2016)
Herceptin Sales by Indication (2008-2016)
MabThera/Rituxan Sales by Indication (2008-2016)
Nexavar Sales by Indication
Provenge Sales (2010-2016)
Sutent Sales by Indication (2008-2016)
Efficacy Results for Erlotinib+Gemcitabine in the Treatment of Pancreatic Cancer
Tarceva Sales by Company (2008-2016)
Tasigna Sales by Indication (2008-2016)
Efficacy of Docetaxel in the Treatment of NSCLC Patients Previously Treated with a Platinum-Based CT Regimen (Intent-to-Treat Analysis)
Taxotere Sales by Indication (2008-2016)
Tykerb/Tyverb Sales by Indication (2008-2016)
Velcade Sales by Company (2008-2016)
Velcade Sales by Indication (2008-2016)
Xeloda Sales by Company (2008-2016)
Xeloda Sales by Indication (2008-2016)
Zoladex Sales by Indication (2008-2016)
Zometa Sales (2008-2016)

LIST OF CHARTS

Oncology Products, 2009
Oncology Products, 2016
Competitor Ratio Analysis Scores
Oncology Blockbuster Product Sales, 2009
Company Share of Oncology Blockbusters, 2009
Therapy Split for Oncology Blockbusters, 2009
Oncology Blockbuster Product Sales, 2016
Company Share of Oncology Blockbusters, 2016
Therapy Split for Oncology Blockbusters, 2016
Alimta Sales (2008-2016)
Arimidex Total Sales (2008-2016)
Avastin Mode of Action
Avastin Sales by Company (2008-2016)
Avastin Sales by Indication, 2009
Avastin Sales by Indication, 2016
Eloxatin Sales (2008-2016)
Erbitux Sales (2008-2016)
Femara Sales by Company (2008-2016)
Gemzar Sales (2008-2016)
Glivec/Gleevec Sales (2008-2016)
HER2 Signalling Pathway
Herceptin Sales (2008-2016)
MabThera/Rituxan Sales (2008-2016)
Nexavar’s Dual Mode of Action
Nexavar Total Sales (2008-2016)
Nexavar Sales by Indication, 2009
Nexavar Sales by Indication, 2016
Schematic of Sipuleucel-T’s Mechanism of Action
Provenge Sales (2010-2016)
Sutent Mode of Action
Sutent Sales (2008-2016)
Sutent Sales by Indication, 2009
Sutent Sales by Indication, 2016
Tarceva Sales by Company (2008-2016)
Tasigna Sales (2008-2016)
TAX 317 Survival K_M Curves - Docetaxel 75mg/m2 vs Best Supportive Care
TAX 320 Survival K_M Curves - Docetaxel 75mg/m2 vs Vinorelbine or Ifosfamide Control
Taxotere Sales (2008-2016)
Taxotere Sales by Indication (2008)
Taxotere Sales by Indication (2016)
Tykerb/Tyverb Total Sales (2008-2016)
Tykerb Sales by Indication, 2009
Tykerb Sales by Indication, 2016
Velcade Sales by Company (2008-2016)
Xeloda Sales (2008-2016)
Xeloda Sales by Indication (2009)
Xeloda Sales by Indication (2016)
Zoladex Sales (2008-2016)
Zoladex Sales By Indication, 2008
Zoladex Sales By Indication, 2016
Zometa Sales (2008-2016)
Skip to top


Liver Cancer Drugs: Market Research Report US$ 3,950.00 Apr, 2010 · 506 pages
Pancreatic Cancer Drugs: Market Research Report US$ 3,450.00 Apr, 2010 · 405 pages
Kidney Cancer Drugs: Market Research Report US$ 4,500.00 May, 2012 · 297 pages

Ask Your Question

Cancer Drug Blockbusters
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: